We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Permanent Ventricular Assist System

By HospiMedica staff writers
Posted on 21 Mar 2001
A left ventricular assist system (LVAS), now in clinical trials, is designed for congestive heart failure (CHF) patients who are no longer responsive to medical management and for whom the only hope is a donor heart transplant.

Called LionHeart, the LVAS is fully implanted in the body and does not replace the heart but assists in the pumping function of the heart's left ventricle. More...
The device is electrically driven by a wearable battery pack that transmits power noninvasively through the skin to charge internal batteries and power the blood pump, with no cables or lines extending through the skin. The internal batteries make it possible for the user to remove the wearable battery pack for short periods, for a shower, for example.

The LionHeart was first implanted in October 1999 in a patient at The Heart and Diabetes Center in Bad Oeynhausen (Germany). The patient is living at home now and the LionHeart continues to function as expected. The device is the result of an eight-year joint development effort involving Hershey Medical Center (Hershey, PA, USA) and Arrow International, Inc. (Reading, PA, USA), which will market the device.

Arrow says LionHeart is the first fully implantable permanent device of its kind and represents a significant advance in mechanical circulatory-assist technology. A phase I human clinical trial is now underway, in which up to seven patients will be implanted with LionHeart. "We expect the clinical trials to show that the unique features of the Arrow LionHeart LVAS will provide significantly improved mobility and quality of life for CHF patients,” said Marlin Miller, Jr., chairman and CEO of Arrow.



Related Links:
Arrow International

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.